intermittent fasting on glp-1 Can you combine with medications for weight loss? Intermittent fasting and GLP-1: combining

Such an approach aligns with modern public health priorities, offering the potential to reduce colorectal cancer incidence while simultaneously addressing obesity, diabetes, and cardiovascular disease

It usually happens early on and tends to settle down with time

Hypothetical Dosing Considerations While no evidence-based cagrilintide dosage with retatrutide protocol exists, theoretical frameworks based on monotherapy data suggest several principles that would likely apply: Conservative Approach Principles: Start with minimal doses Perhaps 0.3 mg cagrilintide + 2 mg retatrutide weekly Extended titration periods 16-24 weeks to reach target doses instead of standard 8-12 weeks Alternating escalation Increase one compound while holding the other stable Frequent monitoring Weekly check-ins during initial phases Lower maximum doses Perhaps 1.2 mg cagrilintide + 8 mg retatrutide rather than maximum monotherapy doses These suggestions remain purely speculative and should not be interpreted as clinical recommendations

Semaglutide trials showed average weight reductions of 10 to 15 pounds over 68 weeks, while tirzepatidea dual GIP/GLP-1 receptor agonistachieved weight losses of 15 to 22 pounds in similar timeframes

Higher NAD+ levels upregulate these pathways